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1. Introduction
Osteoporosis is a very important health problem worldwide. It is defined as a disease charac‐
terized by low bone mass and micro-architectural deterioration of bone tissue, leading to
enhanced bone fragility and consequent increase in fracture risk [1]. Osteoporosis is a silent
disease and the health and financial impact of the disease result from fracture, particularly hip
fracture, for which subjects with osteoporosis are at an increased risk [2]. In the UK, one in two
women and one in five men suffer a fracture after the age of 50, with an annual cost to the
health services of around £2 billion [3,4].
In 1990, the number of osteoporotic fractures estimated in Europe was 2.7 million, with an
estimated direct cost in 2004 of €36 billion (£24.5 billion), of which €24.3 billion (£16.6 billion)
were accounted for by hip fracture. Costs are expected to rise to €76.8 billion (£52.4 billion) by
the year 2050 [5]. Similar projections are made for many other regions of the world because of
the increasing numbers of the elderly. In the USA, the annual cost of incident fractures due to
osteoporosis or low bone mass is predicted to rise from $16.9 billion in 2006 to around $25.3
billion by the year 2025 [4]. The direct costs of medical care of hip fractures were over $65
million in 2004 [6].
There are many hormones involved in bone and mineral metabolism, such as oestrogens,
testosterone and parathormone (PTH). The adipocyte also plays an important role in regulat‐
ing bone metabolism by releasing estrogens, and the adipokines, like leptin, resistin, adipo‐
nectin, and many others. After the discovery of leptin receptors in bone many studies have
been done to explore its involvement in bone metabolism. Some studies have shown that leptin
is expressed and secreted from primary cultures of human osteoblasts during the mineraliza‐
tion period, and that it may stimulate osteogenesis in human bone marrow in vitro [7,8].
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Furthermore, leptin may reduce ovariectomy-induced osteoporosis in rats and may also be
involved in foetal and growing bone metabolism [9, 10].
Leptin, a fat-derived cytokine-like hormone, was discovered in 1994 by Friedman and
colleagues [11]. A 16-kDa hormone, encoded by the OB gene, is predominantly expressed in
adipose tissue [12] and circulates as a free and as a protein-bound entity. According to
structural studies leptin belongs to the growth hormone four-helical cytokine subfamily. The
leptin receptor was identified in the db locus of mouse chromosome 4. As a member of the
IL-6 receptor family, the leptin receptor contains an extracellular-binding domain, a single
transmembrane domain and a cytoplasmatic signaling domain [13]. Intracellular signaling is
mediated through a non-covalently associated tyrosine kinase of the JAK kinase family [14].
Alternate gene splicing results in five known isoforms of the leptin receptor. The longest form
of the receptor (ObR) is the only isoform capable of complete signal transduction. Conversely,
the shorter isoforms of the leptin receptor have been suggested to participate in leptin clearance
and/or to facilitate transport of leptin across the blood-brain barrier [14]. Circulating levels of
leptin correlate with BMI and the content of fat mass. After crossing the blood–brain barrier,
leptin reaches the hypothalamus, where it acts as a crucial regulator of feeding. Leptin is mainly
regarded as a ‘‘starvation-hormone’’ signaling from the adipose tissue (AT) to the brain,
indicating the size of the AT-stores [15].
Food intake and energy expenditure are controlled by leptin through an interaction with
various neuropeptides in the hypothalamus. Neuropeptide Y (NPY) and agouti-related
peptide (AGRP) expressions are inhibited, whereas pro-opiomelanocortin (POMC) expression
is stimulated by leptin with increased food intake [16, 17]. Moreover, leptin interacts with
neuromedin U (NMU); a novel and recently identified hypothalamic neuropeptide involved
also in the regulation of appetite and locomotor activity [18]. Besides energy metabolism, leptin
demonstrates pleiotropic effects in such areas as hematopoesis, blood pressure, T lymphocyte
function, reproduction and bone mass regulation [14, 19]. Several endocrine and paracrine
factors play a role in the fat-bone relationship. A number of local cytokines secreted by the
adipose tissue, including leptin, have also been related to BMD variations [20]. Leptin because
of its diverse role in bone is being considered one of the main functional connections between
fat and bone.
Leptin, known to regulate appetite & energy expenditure may also contribute to mediate
the effects of fat mass on bone. Interestingly, obesity seems to protect from osteoporosis.
This observation led to researchers at bone formation in mouse models of obesity. Much
effort has been dedicated to the relationship between leptin and bone. This interest stems
from the well-founded knowledge that body weight is a major determinant of bone den‐
sity [21].  It  is  known that  obesity is  generally accompanied by increased bone strength.
Obese persons have stronger bones and lose bone tissue at a slower pace [22]. Leptin has
been  proposed  to  regulate  increased  body  weight  as  well  as  increased  bone  density.
Mice  that  have  congenital  absence  of  leptin  (ob/ob)  have  been  shown to  be  obese  and
have very high bone density.  Leptin makes them lose both fat  and bone [23].  The bone
mass phenotype of  ob/ob mice can be rescued by intracerebroventricular  (ICV) infusion
of leptin, suggesting that leptin exerts an indirect influence on bone mass. There is a re‐
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port which has shown that when leptin injected into the brain of animals it  will  inhibit
bone formation at  doses lower than those that  cause loss  of  body weight  [24].  A lot  of
studies have been done to explore the relationship of serum leptin with bone mass den‐
sity and biochemical bone markers in osteoporosis. In this chapter, the mechanism of ac‐
tion of leptin on bone is reviewed and role of serum leptin in postmenopausal females is
discussed  with  respect  to  its  relation  with  bone  mass  density  and  biochemical  bone
markers.
2. Leptin and its mechanism of action on bone
Leptin acts on bone by two different mechanisms. The first is the indirect mechanism revealed
by Ducy et al (2000) in mutant mice and rats that either cannot produce or cannot respond to
leptin [25]. Leptin secreted from fat cells is carried by the ObRa receptors of vascular endo‐
thelial cells across the blood-brain-barrier where it activates ObRb receptors in the hypothal‐
amus. These signals then stimulate expression of HOBIF (hypothalamic osteoblast inhibitory
factor) which when released, lowers the matrix-making ability of osteoblasts [25-29] and
because of this reason obese Ob (Lep)–/– mice, which should have low bone mass due to lack
of leptin, and thus estrogen, actually have an abnormally high bone mass.
The  second  direct  mechanism  of  leptin  action  is  by  promoting  differentiation  of  bone
marrow  stromal  cells  into  osteoblasts  [8]  and  by  inhibiting  osteoclast  generation  [30].
Bone marrow stromal  cells  (BMSC) can differentiate  into either  adipocytes  or  osteoblast
cell  lineage.  Bone marrow adipocytes may serve as  a  direct  source of  leptin,  which can
inhibits adipogenesis differentiation of BMSC and stimulates differentiation of osteoblasts
[31] while Kim et al. (2003) have shown that very high leptin levels led to BMSC apopto‐
sis  [32].  Reseland et  al.  (2001)  have found that  human osteoblasts  start  making and se‐
creting  leptin  when  they  are  either  in  the  late,  matrix-mineralizing  stage  or  when
changing to osteocytes [7]. Leptin has also stimulates the proliferation of cultured human
osteoblasts [33], and it has been shown to cause human bone marrow stromal cells to ex‐
press  alkaline  phosphatase,  collagen-I,  and  osteocalcin  and  to  mineralize  matrix  [8].
These tissue culture experiments support the dual effect of leptin within the bone micro‐
environment depending on the local leptin concentration.
In the last decade Ducy et al.  (2000a,b) [25,27] have not found any long isoforms of the
leptin  receptors  (Ob-R)  on  osteoblasts,  so  they  assumed that  leptin  acted  centrally  as  a
very potent inhibitor of bone formation. Although the long isoform of Ob-R is abundant‐
ly  expressed  in  the  hypothalamus,  and  in  a  large  number  of  peripheral  tissues  [14].
BMSC,  osteoblasts,  osteoclasts  and chondrocytes  also express  leptin receptors  [8].  In  os‐
teoblasts,  leptin acts  through the osteoprotegerin (OPG)/RANKL (Receptor  Activator  for
Nuclear  factor  κB  Ligand)  signaling  pathway.  Treatment  with  leptin  changes  the  OPG/
RANKL  expression  profile  favoring  OPG  [30].  Consequently,  osteoclastogenesis  is  very
likely  suppressed  by  leptin  through  the  OPG/RANKL  pathway.  In  agreement  with  the
previous findings, Burguera et al [10] have also confirmed the previous findings that ad‐
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ministration of leptin reduced ovariectomy induced bone loss in rats by increasing osteo‐
protegerin  mRNA  in  osteoblasts.  Cornish  et  al  in  2001  have  found  that  leptin  given
peripherally  increased  bone  strength  in  mice  and  also  increased  proliferation  of  osteo‐
blasts  in  vitro  [34].  The results  of  these  studies  showed that  direct  peripheral  action of
leptin on bone is to enhance the strength of the bone in contrast to its central effect.
In order to evaluate its central effect, leptin was injected into the brain in the form of an
intra-cerebelo-ventricular infusion [25, 27, 35]. Bone loss occurred in both wild-type mice
and leptin  deficient  mice  confirming that  bone mass  is  partly  regulated via  the  central,
hypothalamic relay [25]. However, bone formation was inhibited at lower doses of leptin
than those necessary to cause the loss of body weight. Ob/ob mice have low sympathetic
activity, which led to the assumption that the central effect of leptin on bone is mediated
by  the  sympathetic  nervous  system (SNS)  [36].  The  effect  of  leptin  on  the  sympathetic
nervous system is an important aspect in the regulation of energy homeostasis as well as
several other physiological functions [37].
3. Serum leptin and Bone Mass Density (BMD)
It is widely recognized that BMD measurement can predict fracture risk in the same way as
cholesterol predicts cardiovascular disease [38]. In fact, the strength of BMD measurement to
predict fracture is approx 3 fold higher than strength of serum cholesterol to predict cardio‐
vascular disease [39]. Bone mass measurement has been found to be a single best predictor of
fracture risk and is required to the early diagnosis of osteoporosis [37,38,39].
It is observed in a study by Lateef et al 2010 that BMD is found to be significantly lower in
postmenopausal females with and without osteoporosis as compared to premenopausal
females [40] and there is a negative correlation between age and BMD found in post meno‐
pausal ostreoporotic females indicating bone loss with age and menopause [41]. A rapid bone
loss is commonly seen in elderly individuals and tends to worsen with advancing age. The
aging population is inevitably proven to be more osteoporotic unless it is intervened first with
diagnostic tools and after preventive therapy [42].
Another study of Lateef et al 2011 showed that plasma leptin levels were positively correlated
with bone mineral density (BMD) values in osteoporotic females [43]. Some reports have
suggested a correlation between serum leptin concentration and BMD while other showed no
such association [44-48]. It has been shown that plasma leptin levels are positively correlated
with BMD at all skeleton sites measured in postmenopausal osteoporosis [49]. It is interesting
to note that the obese are usually protected against osteoporosis and have increased bone
mineral density [50]. This has been attributed to the mechanical effects of their excessive weight
on bone tissue. It has been shown that obese postmenopausal women have a tendency to have
increased bone mineral density compared with lean women [51-53]. The study of Di Carlo et
al. (2007) documented a significant correlation between serum leptin and BMD in early
postmenopausal women but the correlation was lost during progression of the postmeno‐
pausal period [54]. Thomas et al. (2001) have observed that serum leptin correlated with BMD
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in women but not in men [31]. Sato et al. (2001) have found a positive correlation between
serum leptin and calcaneus BMD in men, but the relationship became inverse when adjusted
for body weight [18]. Pasco et al. (2001) have demonstrated a significant positive association
between BMD and serum leptin in non-obese women [55]. Results of Blain et al (2002) reported
that leptin is an independent predictor of whole body and femoral neck BMD in postmeno‐
pausal women [56]. Nagy et al. (2001) found a negative correlation between serum leptin levels
and radial and femoral BMD in postmenopausal women [57]. Hadji et al. (2001) reported that
bone mass is not correlated with the serum leptin level in pre or postmenopausal women [58].
Rauch et al. (1998) also reported no correlation between bone mass and serum leptin levels by
examining total and trabecular bone density at the distal radius in adult women [59]. In leptin
literature, several studies have examined the relationship between serum leptin and BMD in
various cohorts, but the results remain contradictory. This fact reflects the intricacy of the
relationship of leptin and bone.
A study by  Hamrick  and Ferrari  (2008)  has  documented that  the  effect  of  leptin  is  re‐
duced  with  increased  age  and  higher  BMI  in  both  humans  and  laboratory  animals  in
spite  of  high serum leptin levels  [60].  It  has been postulated that  the under-responsive‐
ness  to  leptin,  or  leptin  resistance,  is  mediated  either  by  impaired  transport  of  leptin
through the blood-brain barrier, lower expression of leptin receptors and/or by the inhib‐
ition of  the intracellular  leptin signaling [61].  In plasma,  leptin is  bound to soluble  lep‐
tin  receptor  (SLR),  the  product  of  an  alternate  splicing  of  leptin  receptor  mRNA  or
proteolytic cleavage [14]. Whereas serum leptin levels correlate positively with BMI, SLR
is correlated negatively [14,62]. The inverse relationship between SLR and BMI reflects a
feedback regulation between the body weight  and leptin or  leptin  receptor  expressions.
It  is  observed in a study by Welt  et  al.  (2004)  when low serum leptin levels  in women
with hypothalamic amenorrhea (induced either by exercise or by low body weight) were
treated with recombinant human leptin for three months,  it  led to an increase of  osteo‐
calcin,  bone  alkaline  phosphates  and  IGF-1,  whereas  urinary  N-telopeptide  did  not
change  [63].They  have  demonstrated  that  leptin  administration  in  individuals  with  lep‐
tin  deficiency appeared to  improve the  growth hormone axis  and markers  of  bone for‐
mation [63].
4. Osteoporosis and bone turnover markers (BTMs)
Bone markers are product derived from the bone remodeling process. During this process,
compounds are released either from bone or from the cells involved in the bone remodeling
process (osteoblasts and osteoclasts.) Markers of bone turnover are biochemical products
measured usually in blood or urine that reflect the metabolic activity of bone but which
themselves have no function in controlling skeletal metabolism [64]. Biochemical markers of
bone turnover are broadly divided into two categories: markers of bone resorption, which
reflect osteoclast activity and are for the most part degradation products of type I collagen;
markers of bone formation, which reflect osteoblast activity and are byproducts of collagen
synthesis, matrix proteins or osteoblastic enzymes (Table 1) [65].
Serum Leptin and Bone Turnover Markers in Postmenopausal Osteoporosis
http://dx.doi.org/10.5772/54527
71
Bone formation Detected in
Byproducts of collagen synthesis
Procollagen type I C-terminal propeptides (P1CP) Serum
Procollagen type I N-terminal propeptides (PINP) Serum/Plasma
Matrix protein
Osteocalcins (OC) Serum/Plasma
Osteoblast enzyme
Bone alkaline phosphatases (BALP) Serum
Bone resorption Detected in
Collagen degradation products
Hydroxyprolin Urine
Pyridinolin(PYD) Urine
Deoxypyridinoline (DPD) Urine
Cross-linked telopeptides of type I collagen
N-terminal cross-linked telopeptide (NTX) Urine and serum/plasma
C-terminal cross-linked telopeptide (CTX) Urine and serum/plasma
Osteoclast enzymes
Tartrate-resistant acid phosphatases (TRACP) Serum
Table 1. List of important biochemical markers of bone turnover
5. Markers of bone formation
Bone formation markers are direct or indirect products of active osteoblasts expressed during
different phases of osteoblast development and reflecting different aspects of osteoblast
function and bone formation. All markers are measured in serum or plasma [66].
5.1. Alkaline phosphatase
Alkaline phosphatase (ALP) is a ubiquitous enzyme that plays an important role in osteoid
formation and mineralization. The total ALP serum pool consists of several dimeric isoforms
which originate from various tissues such as liver, bone, intestine, spleen, kidney and placenta.
In adults with normal liver function, approximately 50% of the total ALP activity in serum
arises from liver and 50% arise from bone [67].
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5.2. Bone specific alkaline phosphatase
Bone specific alkaline phosphatase (BALP) is one of several isoenzymes of the alkaline
phosphatase (ALP) family. The entire family is encoded by four gene loci, three tissue specific
genes (bone,kidney,liver and other tissues). Although the nonspecific ALPs are the products
of a single gene, the ioenzymes present in tissues such as bone, kidney or liver vary greatly
because of variations in their carbohydrate side chains. These post translational modifications
are exploited to distinguish the various ALP-isoforms from each other, employing methods
including gel electrophoresis, heat denaturation, chemical inhibition or binding through
specific monoclonal antibodies [68]. For therapeutic monitoring of patients, B-ALP measure‐
ments are good indicators of the metabolic activity of bone. Rising ALP concentrations may
indicate estrogen deficiency [69,70].
5.3. Osteocalcin
Osteocalcin (OC) is a small, hydroxyapetite-binding protein synthesized by osteoblasts and to
a lesser extent by hypertrophic chondrocytes. It contains three gamma- carboxyglutamic acid
(Gla) residues which are responsible for calcium binding properties of protein. The precise
function of osteocalcin has yet to be determined but recent studies suggest that OC is involved
in bone remodeling via a negative mechanism. Serum osteocalcin is considered as a specific
marker of osteoblast function, as its levels correlate with bone formation rates. However, the
peptide is rapidly degraded in serum and both intact peptides and OC fragments of various
sizes coexist in the circulation [70]. Osteocalcin is normally considered as bone formation
marker. However, because it is released during bone formation from bone forming cells and
during bone resorption from bone matrix, it reflects the overall turnover of bone. Assays have
been developed to detect the intact protein and or the main breakdown product called N-mid
fragment. OC serum levels follow a circadian rhythm with high values in early morning, but
usually not influenced by food intake. Serum osteocalcin levels reportedly vary significantly
during the menstrual cycle with the highest level observerd during luteal phase [71].
5.4. Amino & carboxyterminal procollagen propeptides of type I collagen
The amino and carboxy terminal procollagen propeptides of type I collagen (PINP, PICP) are
cleaved by specific extracellular endopeptidases from newly translated collagen type I
pepetide. As these extension peptides are generated in a stoichiometric relationship with
collagen biosynthesis, they are considered quantitative measures of newly formed type I
collagen. However, because type I collagen is also a component of several soft tissues (fibro‐
cartilage, tendon, skin, gingival, intestine, heart valve, and large vessels) there is potential
contribution to circulating procollagens from soft tissue synthesis of type I collagen. Both PICP
and PINP demonstrate a cardian rhythm with peak values in the early morning, and are
usually not influenced by food intake. Serum levels of amino and carboxy terminal procollagen
propeptides of type I collagen (PINP, PICP) are measured by type and site specific immuno‐
assays [66]. Moderate correlations between serum PICP levels and the rate of bone formation
have been reported [72].
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5.5. Markers of bone resorption
Most biochemical markers of bone resorption are degradation products of bone collagen, but
noncollagenous proteins such as bone sialoprotein or tartarate resistant acid phosphatase have
also been investigated [73].
5.6. Hydroxy proline
Hydroxyproline is an amino acid common to and characteristic of all forms of collagen, and
urinary hydroxyproline excretion is the oldest test of bone resorption. However, this test lacks
specificity for bone resorption because excreted hydroxyproline also comes from other tissues,
particularly from skin collagen (which can turn over rapidly in certain disorders), from newly
synthesized collagen that is not incorporated into tissue, and from dietary collagen and gelatin.
Because it is less specific than newer tests, it is no longer widely used [74].
5.7. Pyridinoline (Pyr) and Deoxypyridinoline (DPD)
The pyridinum crosslinks pyridinoline (PYD) and deoxypyridinolin (DPD) are the main
crosslinks in skeletal tissues but act as stabilizers of mature croslinks in type I, II & III collagens
of all major connective tissues (bone, dentin, ligaments, tendons, vascular walls, muscle and
intestine) except skin. While PYD predominates in most tissues, DPD is most abundant in bone
and therefore is considered the more specific marker [75].
5.8. Crosslinked Telopeptides
The term “crosslinked telopeptides” refers to the measurement of collagen degradation
products associated with the crosslink regions in type I collagen. Fragments derived from the
C terminus are also released into circulation as a result of the osteoclast-mediated degradation
of type I collagen and can be measured by various assays [76, 77]. The immuno reactive
epitopes are located on peptide fragments derived from the N terminal (NTX-1) and C terminal
(CTX-1 and ICTP) telopeptides of the collagen type I molecule. The NTX-1 and CTX-1 epitopes
can be measured in both serum and in urine [78, 79].
6. Tatartarate Resistant Acid Phosphatase (TRACP)
Tartarate resistant acid phosphate is synthesized and secreted by osteoclasts during active
bone resorption. The process of resorption occurs after the attachment of osteoclasts to the
bone surface and follows the secretion of acid and enzymes into a space created between the
osteoclast and the bone. The acidic environment is produced by the action of carbonic
anhydrase and an H-ATPase proton pump. TRACP, one of the enzymes secreted into this
space, has been located in the adjacent osteoclast membrane (known as the ruffled border) [80].
Its activity in serum reflects bone resorption rates and more recently it has been possible to
measure the isoenzyme by very specific immunoassays
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The use of biochemical markers of bone remodeling in the monitoring of patients on treatment
for osteoporosis is generally well-recognized [81,82]. However, optimum treatment targets
specific to various therapies and the benefits of monitoring in terms of improvement in fracture
outcomes or in adherence to oral therapies are not established [83].
The changes in BMD and BTMs following the initiation of osteoporosis treatment independ‐
ently correlate with fracture risk reduction [84]. The advantage of BTM over BDM is that the
change in BTMs following treatment explains a greater proportion of treatment as compared
to BMD does, in terms of fracture risk reduction [85,86]. Also, the change in BMD is small and
slow whereas the changes in BTMs are large and occur early after initiation of therapy. Repeat
BMD is not advocated within 12 months after initiation of therapy as the changes do not
generally attain significance within that time, and in fact 18-24 months may be appropriate for
repeat BMD measurements [87]. BTMs on the other hand show significant change by 3-6
months. For example, bone resorption markers can be measured 3 months after initiation of
oral bisphosphonates, and bone formation markers 6 months after start of therapy [88, 89).
Changes in BTMs may be useful in monitoring osteoporosis treatment to confirm compliance
with oral therapies and efficacy of treatment [90].
There are many studies which have demonstrated BTMs and their contribution to fracture risk,
but the results of these studies have been inconsistent [91-95]. Many studies which have shown
positive results with BTMs included bone resorption markers, with increased resorption
marker predicting an increased fracture risk. While for BTMs to predict fracture risk inde‐
pendently of BMD, it is needed to clarify their relationships to other established risk factors.
The changes in BTMs following therapy are well documented. There is a decrease in BTMs
following initiation of anti-resorptive therapy, reflecting inhibition of osteoclastic activity
[96-100]. For example, with bisphosphonate treatment, there is a decrease in bone resorption
markers within days following intravenous therapy, and within weeks following oral therapy.
Vasikaran et al [83] supports the role of BTMs in the management of patients with osteoporosis
and also emphasized on the adoption of international reference standards for enhancing
laboratory consistency and to facilitate their inclusion in routine clinical practice.
The problem in BTMs use is their wide biological and analytical variability, Glover et al [101]
emphasized that reference ranges should be defined and standardized with emphasis on
sample size and age range of the population. Sandhu & Hampson (2011) describe that the best
established clinical use for BTMs is in monitoring treatment efficacy and compliance [102]. In
a study by Kim et al observed that BMT can be used to determine BMD response to antire‐
sorptive therapy in Korean postmenopausal osteoporotic females [103].
The Scientific Advisory Council of Osteoporosis Canada including multidisciplinary working
group stated about the bone turnover markers in the management of postmenopausal
osteoporosis that as far as potential uses of bone turn over markers (BTMs) are concerned, they
can be used to predict bone loss and fracture in untreated postmenopausal women. They can
also be used to monitor osteoporosis therapy, and up to some extent enhance the adherence
to therapy but BTMs should not be used for diagnosis of osteoporosis as s separate and
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independent factor. Similarly it must not be used to select the most appropriate type of
osteoporotic therapy for the treatment. [104].
7. Relationship of leptin with bone markers in post menopausal
osteoporotic females
Data in the literature are inconsistent and conflicting about the relationship of leptin with
bone markers in post menopausal osteoporotic females. The study of Goulding & Taylor
(1998) was the first to examine relationships among plasma levels of leptin, and dynamic bi‐
ochemical markers of bone cell activity in postmenopausal women [46]. This study demon‐
strated no association between circulating plasma levels of leptin and biochemical markers
of either osteoclastic or osteoblastic activity. They concluded that leptin itself does not play
any significant direct role in controlling bone cell activity in postmenopausal women.
Scariano et al reported positive association between serum leptin and bone specific alkaline
phosphatase in postmenopausal women and elderly men after adjustment for BMD, age and
BMI [105]. The association of circulating leptin levels with bAP, a specific marker of osteo‐
blast activity suggests that leptin levels influence osteoblast activity in vivo in elderly wom‐
en and men. In a cross sectional study by Filip R & Raszewski G (2009) a positive association
between leptin and osteocalcin in older patients with hip fracture [106]. Rauch et al. and La‐
teef et al also found no relationship between plasma leptin level and bone turnover markers
in adult women and postmenopausal osteoporotic females respectively [40,59]. Filip & Ras‐
zewski et al, found no correlations of serum leptin with lumber spine BMD, femoral neck
BMD, biochemical markers of bone turnover with leptin, in overweight and obese postme‐
nopausal women, even after stratification of the study group by BMI ratio value (25–29 9,
30–39 9 and ≥ 40), or by waist: hip ratio (WHR), ratio value (< 0 85 and ≥ 0 85) [106]. In a
small study, Iwamoto et al. (2000) found correlations between serum leptin and bone re‐
modelling markers only in premenopausal women [107]. Peng et al (2008) reported no asso‐
ciation between serum leptin and bone turnover biochemical markers in men [108].
In postmenopausal osteoporotic patients with increased bone turnover, serum leptin con‐
centration is not correlated with BMD or with the biomarkers of bone formation or bone re‐
sorption [109]. According to few studies performed in China no correlation found between
serum leptin and bone turnover biochemical markers in post-menopausal Chinese women
[110-112]. Similarly, no correlation observed between leptin and bone turnover markers in
Chinese adolescent dancers and control group in one more study (101) Blain, et al (2002) re‐
ported that serum leptin level was positively correlated with weight, fat mass, BMI, E2, crea‐
tinine clearance, and BAP level and inversely correlated with urine CTx [56]. They
supported the suggestion that circulating leptin exerts its protective effect on bone through
limiting the excessive bone resorption coupled with bone formation that is associated with
bone loss after menopause.
Prouteau et al (2006) suggested a regulatory role of leptin on type I collagen metabolism [113].
The negative association between bone resorption (CTx levels) and serum leptin levels
observed at baseline (stable body weight) was further confirmed by the biochemical changes
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occurring in responses to weight loss and weight regain. The drop in leptin levels was strongly
related to the increase in bone resorption marker occurring in response to weight loss.
Similarly, after weight regain the rise in leptin levels was associated with a concomitant
decrease in bone resorption. The reasons for these discrepancies need to be clarified.
8. Conclusion
The relationship of leptin and bone turnover markers in post menopausal osteoporosis has not
yet been clarified. Although several studies have been done but still there is need to explore
their exact connection. Many studies have recommended that in the treatment of the post-men‐
opausal women, biochemical markers of bone turnover may be useful as adjuncts to BMD and
other diagnostic tests. They can be mainly used to monitor response to treatment and also used
as relatively economical tools for studying bone metabolism. The exact roles of BTM need to be
established in clinical practice. It is suggested that repeated measurements of bone markers
during anti-resorptive therapy may help to improve the management of osteoporotic patients.
Both a peripheral and a central action of leptin on bone metabolism have been suggested. Pe‐
ripherally, leptin is thought to exert positive effects on bone formation, whereas it is thought to
reduce bone formation via a central control mechanism when binding to its specific receptors
located on the hypothalamic nuclei [26]. It has been suggested that circulating leptin may act
positively to maintain bone mass but these effects of serum leptin are not mediated due to these
biochemical markers. Despite a preliminary understanding of leptin–bone mass interactions,
the exact roles of leptin on bone metabolism have not yet been elucidated.
The role of BTMs in monitoring osteoporosis treatment to confirm compliance with oral
therapies, and efficacy of treatment has been established. Further studies with reference to
serum leptin and BTMs in post menopausal osteoporotic females are needed to clarify their
association and significance of that association in treatment targets for various therapies and
optimal monitoring regimes.
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